Equity Profile

KRYS

Krystal Biotech, Inc.

Health CareBiotechnology$10.7B

Mar18Mon

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Krystal Biotech, Inc. is a biotechnology company focused on developing gene therapies for rare diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and performance this quarter.

N/A

Revenue Growth

Investors will be looking for any signs of revenue growth, which can indicate market demand for Krystal's therapies.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

KRYS Q2-2026 Earnings Preview

Context

Company Snapshot

Krystal Biotech, Inc. is a biotechnology company focused on developing gene therapies for rare diseases. With a market cap of $11 billion, it operates in the health care sector, aiming to leverage innovative treatments to address unmet medical needs.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+23.84%

Avg Stock Reaction

-1.56%

Last Quarter Recap

In the last quarter, Krystal Biotech reported an EPS of $1.83, surpassing estimates by 26.21%. The stock reacted positively, gaining 7.86% the following day.

Management Promises & Guidance

Continued focus on advancing gene therapy programs.
Commitment to exploring new indications for existing therapies.
Plans to enhance operational efficiency.

Expectations

Wall Street Expectations

Overall, expectations are mixed as the company has shown strong EPS surprises in recent quarters, but revenue guidance remains unclear.

Bull Case

If Krystal can maintain its trend of beating EPS estimates, it could signal strong operational performance and investor confidence.

Bear Case

Conversely, if the company fails to meet expectations or provides weak guidance, it could lead to significant stock declines.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be this quarter, and how does it compare to previous quarters?

Given the company's recent strong EPS performance, investors will closely watch this metric to gauge ongoing profitability.

What are the updates on the pipeline of gene therapies?

Insights into the progress of their therapies could significantly impact investor sentiment and future revenue potential.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the potential for Krystal's therapies to capture market share, especially given the recent positive EPS surprises.

Supporting Evidence

Krystal has consistently beaten EPS estimates, indicating stronger-than-expected performance.

The options market is pricing in a smaller move than the historical average, suggesting potential for a larger reaction.

The company's commitment to R&D could lead to breakthroughs that are not yet reflected in current valuations.

Key Risk

If the pipeline shows significant advancements, it could shift investor sentiment dramatically.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter centers around whether Krystal can sustain its recent earnings momentum amid ongoing investments in R&D.

Bull Confirmed If

An EPS of $2.00 or higher would confirm strong operational performance and growth.

Bear Confirmed If

An EPS below $1.50 would raise concerns about profitability and future growth prospects.

Pre-Earnings Positioning

Options Market

Implied Move

±3.35%

Historical Avg

±7.7%

Pricing cheap

The options market is pricing in a modest move around the earnings report, suggesting uncertainty but not extreme volatility.

Options are pricing ±3.3% while KRYS has averaged ±7.7% over the last 8 prints — setup is pricing cheap.

Detail

ATM IV

0.4%

30d HV

38.7%

Calls (1K)P/C Ratio: 0.13Puts (3K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options pricing cheap in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Krystal beats expectations, history suggests the stock could rise by about 2.6%, confirming strong operational strength.

In-Line / Cautious

If results are in line but management provides cautious commentary, the stock may see little movement as investors digest the information.

Miss

A miss could lead to a decline of around 14.05%, reflecting disappointment in the company's performance.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the progress of gene therapy trials.
2Any changes in guidance for future EPS or revenue.
3Insights into competitive positioning in the biotechnology space.
4Details on operational efficiencies or cost management strategies.
5Management's outlook on market demand for their therapies.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Gen Digital Inc.

Company Snapshot

Krystal Biotech, Inc. is a biotechnology company focused on developing gene therapies for rare diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and performance this quarter.

N/A

Revenue Growth

Investors will be looking for any signs of revenue growth, which can indicate market demand for Krystal's therapies.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

KRYS Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+23.84%

Avg Stock Reaction

-1.56%

Last Quarter Recap

In the last quarter, Krystal Biotech reported an EPS of $1.83, surpassing estimates by 26.21%. The stock reacted positively, gaining 7.86% the following day.

Management Promises & Guidance

Continued focus on advancing gene therapy programs.
Commitment to exploring new indications for existing therapies.
Plans to enhance operational efficiency.

Expectations

Wall Street Expectations

Overall, expectations are mixed as the company has shown strong EPS surprises in recent quarters, but revenue guidance remains unclear.

Bull Case

If Krystal can maintain its trend of beating EPS estimates, it could signal strong operational performance and investor confidence.

Bear Case

Conversely, if the company fails to meet expectations or provides weak guidance, it could lead to significant stock declines.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be this quarter, and how does it compare to previous quarters?

Given the company's recent strong EPS performance, investors will closely watch this metric to gauge ongoing profitability.

What are the updates on the pipeline of gene therapies?

Insights into the progress of their therapies could significantly impact investor sentiment and future revenue potential.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the potential for Krystal's therapies to capture market share, especially given the recent positive EPS surprises.

Supporting Evidence

Krystal has consistently beaten EPS estimates, indicating stronger-than-expected performance.

The options market is pricing in a smaller move than the historical average, suggesting potential for a larger reaction.

The company's commitment to R&D could lead to breakthroughs that are not yet reflected in current valuations.

Key Risk

If the pipeline shows significant advancements, it could shift investor sentiment dramatically.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter centers around whether Krystal can sustain its recent earnings momentum amid ongoing investments in R&D.

Bull Confirmed If

An EPS of $2.00 or higher would confirm strong operational performance and growth.

Bear Confirmed If

An EPS below $1.50 would raise concerns about profitability and future growth prospects.

Pre-Earnings Positioning

Options Market

Implied Move

±3.35%

Historical Avg

±7.7%

Pricing cheap

The options market is pricing in a modest move around the earnings report, suggesting uncertainty but not extreme volatility.

Options are pricing ±3.3% while KRYS has averaged ±7.7% over the last 8 prints — setup is pricing cheap.

Detail

ATM IV

0.4%

30d HV

38.7%

Calls (1K)P/C Ratio: 0.13Puts (3K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options pricing cheap in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Krystal beats expectations, history suggests the stock could rise by about 2.6%, confirming strong operational strength.

In-Line / Cautious

If results are in line but management provides cautious commentary, the stock may see little movement as investors digest the information.

Miss

A miss could lead to a decline of around 14.05%, reflecting disappointment in the company's performance.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the progress of gene therapy trials.
2Any changes in guidance for future EPS or revenue.
3Insights into competitive positioning in the biotechnology space.
4Details on operational efficiencies or cost management strategies.
5Management's outlook on market demand for their therapies.